InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma
January 6, 2026
TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme, one of the most aggressive forms of brain cancer. The study, conducted in collaboration with Michigan State University and published in the Journal of Functional Biomaterials, demonstrated that systemic delivery of TTX-MC138 successfully reached brain tumors in […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Jack E. Stover to Board of Directors
December 22, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Jack E. Stover to its Board of Directors, where he will serve on the Audit Committee and the Nominating Committee, as Dr. Magda Marquet steps down from the Audit Committee. Mr. Stover brings more than 30 years of executive leadership experience across public and private life sciences companies, with a background spanning […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Launch Collaboration to Evaluate TTX-MC138 in PRE-I-SPY Trial
December 11, 2025
TransCode Therapeutics (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative announced a collaboration to evaluate TransCode’s lead therapeutic candidate TTX-MC138 in the PRE-I-SPY Phase 2a clinical trial platform, which plans to enroll up to 45 colorectal cancer patients who are ctDNA positive following standard curative-intent therapy. Beginning in the first half of 2026 and led by […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Dr. Michel Janicot as Senior Development Officer
November 17, 2025
TransCode Therapeutics (NASDAQ: RNAZ) appointed Dr. Michel Janicot as consultant Senior Development Officer, adding more than 35 years of global oncology drug-development experience to support the advancement of TTX-MC138 and Seviprotimut-L. Dr. Janicot, founder of JMi ONConsulting and former senior leader at Rhône-Poulenc Rorer and Janssen, brings deep expertise in RNA biology, preclinical strategy, translational […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Completes Phase 1a Trial of TTX-MC138, Advancing to Phase 2 Evaluation
October 14, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced completion of its Phase 1a clinical trial of TTX-MC138, an investigational inhibitor of microRNA-10b, achieving its primary safety endpoint and establishing a recommended Phase 2 dose. Sixteen patients were treated with no significant safety events or dose-limiting toxicities observed, and 44% achieved stable disease lasting four months or longer. The […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Acquires Polynoma, Secures $25 Million Investment from CK Life Sciences to Advance Phase 2 Trial of TTX-MC138
October 8, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced it has entered into a definitive agreement to acquire Polynoma LLC, a privately held immuno-oncology company developing seviprotimut-L, a late-stage polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma. Concurrent with the acquisition, TransCode secured a $25 million investment from CK Life Sciences Int’l (Holdings) […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints RNAi Pioneer Phillip Zamore to Scientific Advisory Board
May 28, 2025
TransCode Therapeutics (NASDAQ: RNAZ), has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of Alnylam Pharmaceuticals, to its Scientific Advisory Board. Dr. Zamore, currently Chair of the RNA Therapeutics Institute at UMass Chan Medical School, is renowned for his foundational work in RNA biology and gene silencing mechanisms. […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances RNA Cancer Therapy as 15 Patients Dosed in Phase 1a Trial
May 8, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced that the third patient in Cohort 4 of its Phase 1a trial for RNA-based cancer therapeutic TTX-MC138 has been dosed, with 15 patients now treated across four dose levels. The Safety Review Committee approved expanded enrollment and noted no significant toxicities or disease progression to date. Ten patients remain on […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Sets 1-for-28 Reverse Stock Split Effective May 15
May 6, 2025
TransCode Therapeutics (NASDAQ: RNAZ), the RNA oncology company focused on developing RNA therapeutics to treat cancer, will implement a 1-for-28 reverse stock split effective May 15, 2025, at 12:01 a.m. EDT. Shares will begin trading on a split-adjusted basis that same day under the existing ticker, “RNAZ.” The move, approved by shareholders and the board, […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
May 1, 2025
TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at least one dose across four dosing levels, with no significant toxicities observed. Eight patients remain in the trial, with two showing stable disease after seven months. Early PK/PD […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Adjourns Special Meeting Due to Lack of Quorum
April 22, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced that its April 21 special meeting has been adjourned to May 2 at 9:30 a.m. Eastern after failing to meet the quorum requirement. Only 12.73% of eligible shares were represented, below the one-third threshold. The adjournment is intended to allow further proxy solicitation on two proposals: a reverse stock split […]
InvestorNewsBreaks – TransCode Therapeutics Inc. (NASDAQ: RNAZ) Secures $10M in Registered Direct Offering
March 27, 2025
TransCode (NASDAQ: RNAZ), the oncology company committed to utilizing RNA therapeutics to more effectively treat cancer, has announced the closing of its sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and […]
ROTH MKM to Host 9th Annual London Conference on June 20-22, 2023
June 13, 2023
NEWPORT BEACH, Calif., June 13, 2023 (GLOBE NEWSWIRE) — via IBN — ROTH MKM (“Roth”), www.roth.com, will host the 9th Annual Roth London Conference on June 20-22, 2023, at Four Seasons Hotel London at Park Lane in London, UK. This event will provide institutional investors the unique opportunity to meet with C-suite leaders and executive management teams from approximately 70 […]
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies
November 15, 2021
Virtual: November 16 – 17, 2021 Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 presenting companies from a wide spectrum […]